Back to Trades
Sell4
Orchestra BioMed Holdings, Inc.
OBIO
Total Value
$382
Net $132 sold
Sales
$132
1 transaction
Company Information
- Company Name
- Orchestra BioMed Holdings, Inc.
- Ticker Symbol
- OBIO
- CIK
- 0001814114
Insider Information
- Role
- Insider
- Location
- NEW YORK, NY
Filing Details
- Filing Date
- Apr 29, 2026
- Transaction Date
- Apr 27, 2026
- Accession Number
- 0001231919-26-000427
- Form Type
- 4
- Net Trading Amount
- -$132
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Apr 27, 2026 | Common Stock | 1,250,032 | $0.00 | Exercise | $125 |
| Apr 27, 2026 | Common Stock | 32 | $4.13 | Sale | $132 |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Apr 27, 2026 | Derivative | 1,250,032 | $0.00 | Exercise | $125 |
Footnotes
- (F1)On April 27, 2026, the RTW Funds exercised Pre-Funded Warrants to purchase an aggregate of 1,250,032 shares of the Issuer's common stock for $0.0001 a share. The RTW Funds exercised the Pre-Funded Warrants on a cashless basis, resulting in the Issuer's withholding 32 of such shares to satisfy the exercise price of the Pre-Funded Warrants, and the issuance to the RTW Funds of an aggregate of 1,250,000 shares.
- (F2)Held by certain affiliated funds (the "RTW Funds") managed by RTW Investments, LP ("RTW"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein.
- (F3)The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the RTW Funds shall not be entitled to exercise the Pre-Funded Warrants to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the RTW Funds, together with their Attribution Parties (as defined in the Pre-Funded Warrants), to exceed 19.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.